vTv Therapeutics Inc. (NASDAQ: VTVT) 近日宣布,已与纽斯澳拉生物制药有限公司(Newsoara Biopharma Co. Ltd.)就磷酸二酯酶-4(PDE4)抑制剂HPP737的授权协议条款进行了修订。此次修订旨在调整双方在特定区域内的开发和商业化权利与义务,以更好地适应市场环境与战略需求。HPP737作为一种口服PDE4抑制剂,目前正处于临床开发阶段,主要用于治疗炎症性疾病,其市场潜力备受关注。协议的更新预计将优化资源配置,加速该候选药物的研发进程。
vTv Therapeutics Inc. (NASDAQ: VTVT) 近日宣布,已与纽斯澳拉生物制药有限公司(Newsoara Biopharma Co. Ltd.)就磷酸二酯酶-4(PDE4)抑制剂HPP737的授权协议条款进行了修订。此次修订旨在调整双方在特定区域内的开发和商业化权利与义务,以更好地适应市场环境与战略需求。HPP737作为一种口服PDE4抑制剂,目前正处于临床开发阶段,主要用于治疗炎症性疾病,其市场潜力备受关注。协议的更新预计将优化资源配置,加速该候选药物的研发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.